Autologous Melanoma Vaccine Induces Antitumor and Self-Reactive Immune Responses That Affect Patient Survival and Depend on MHC Class II Expression on Vaccine Cells

No abstract is available for this paper.

• Publication year

  2009

• Venue

  Clinical Cancer Research

• Publication date

  2009-08-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1158/1078-0432.CCR-08-3320PMID 19602547
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Therapeutic vaccines in cancer: moving from immunomonitoring to immunoguiding

  2008cited by this paper
• Treatment of metastatic melanoma with autologous CD4+ T cells against NY-ESO-1.

  2008cited by this paper
• Immunization of Malignant Melanoma Patients with Full-Length NY-ESO-1 Protein Using TLR7 Agonist Imiquimod as Vaccine Adjuvant1

  2008cited by this paper
• Clinical and immunological evaluation of anti-apoptosis protein, survivin-derived peptide vaccine in phase I clinical study for patients with advanced or recurrent breast cancer

  2008cited by this paper
• Vaccine-specific local T cell reactivity in immunotherapy-associated vitiligo in melanoma patients

  2008cited by this paper
• Next generation of immunotherapy for melanoma.

  2008cited by this paper
• An adjuvant autologous therapeutic vaccine (HSPPC-96; vitespen) versus observation alone for patients at high risk of recurrence after nephrectomy for renal cell carcinoma: a multicentre, open-label, randomised phase III trial.

  2008cited by this paper
• Concerted Potent Humoral Immune Responses to Autoantigens Are Associated with Tumor Destruction and Favorable Clinical Outcomes without Autoimmunity

  2008cited by this paper
• Subcellular localization determines the delicate balance between the anti- and pro-apoptotic activity of Livin

  2007cited by this paper
• Immunologic and Clinical Outcomes of a Randomized Phase II Trial of Two Multipeptide Vaccines for Melanoma in the Adjuvant Setting

  2007cited by this paper
• Single administration of low dose cyclophosphamide augments the antitumor effect of dendritic cell vaccine

  2007cited by this paper
• Increase of CD4+CD25+ regulatory T cells in the peripheral blood of patients with metastatic carcinoma: a Phase I clinical trial using cyclophosphamide and immunotherapy to eliminate CD4+CD25+ T lymphocytes

  2007cited by this paper
• Spontaneous and vaccine induced AFP-specific T cell phenotypes in subjects with AFP-positive hepatocellular cancer

  2007cited by this paper
• Tumor‐reactive CD8+ T‐cell clones in patients after NY‐ESO‐1 peptide vaccination

  2007cited by this paper
• Cancer Vaccines: Moving Beyond Current Paradigms

  2007cited by this paper
• Prognostic significance of autoimmunity during treatment of melanoma with interferon.

  2006cited by this paper
• Discontinued drugs in 2005: oncology drugs

  2006cited by this paper
• Synergism between CpG-Containing Oligodeoxynucleotides and IL-2 Causes Dramatic Enhancement of Vaccine-Elicited CD8+ T Cell Responses1

  2006cited by this paper
• Biologic and immunomodulatory events after CTLA‐4 blockade with ticilimumab in patients with advanced malignant melanoma

  2006cited by this paper
• Prognostic significance of autoimmunity during treatment of melanoma with interferon

  2006cited by this paper
• Association of antigen-processing machinery and HLA antigen phenotype of melanoma cells with survival in American Joint Committee on Cancer stage III and IV melanoma patients.

  2006cited by this paper
• Immune suppression in cancer: effects on immune cells, mechanisms and future therapeutic intervention.

  2006cited by this paper
• CD8+ T Cell Immunity Against a Tumor/Self-Antigen Is Augmented by CD4+ T Helper Cells and Hindered by Naturally Occurring T Regulatory Cells

  2005cited by this paper
• Immunomonitoring tumor-specific T cells in delayed-type hypersensitivity skin biopsies after dendritic cell vaccination correlates with clinical outcome.

  2005cited by this paper
• Dendritic cell immunizations alone or combined with low doses of interleukin‐2 induce specific immune responses in melanoma patients

  2005cited by this paper
• Aberrant expression and potency as a cancer immunotherapy target of inhibitor of apoptosis protein family, Livin/ML-IAP in lung cancer.

  2005cited by this paper
• High frequency of antitumor T cells in the blood of melanoma patients before and after vaccination with tumor antigens

  2005cited by this paper
• Immunogenicity, including vitiligo, and feasibility of vaccination with autologous GM-CSF-transduced tumor cells in metastatic melanoma patients.

  2005cited by this paper
• Tumor Progression Can Occur despite the Induction of Very High Levels of Self/Tumor Antigen-Specific CD8+ T Cells in Patients with Melanoma

  2005cited by this paper
• Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma.

  2005cited by this paper
• Synergy of IL-21 and IL-15 in regulating CD8+ T cell expansion and function

  2005cited by this paper
• Tumoral and immunologic response after vaccination of melanoma patients with an ALVAC virus encoding MAGE antigens recognized by T cells.

  2005cited by this paper
• Multiple Costimulatory Modalities Enhance CTL Avidity

  2005cited by this paper
• Phase I/II study of immunotherapy with T-cell peptide epitopes in patients with stage IV melanoma

  2005cited by this paper
• Antitumor activity in melanoma and anti-self responses in a phase I trial with the anti-cytotoxic T lymphocyte-associated antigen 4 monoclonal antibody CP-675,206.

  2005cited by this paper
• The melanoma inhibitor of apoptosis protein: a target for spontaneous cytotoxic T cell responses.

  2004cited by this paper
• Interleukin-2 improves tumour response to DNP-modified autologous vaccine for the treatment of metastatic malignant melanoma

  2004cited by this paper
• Immunopharmacologic analysis of an autologous, hapten-modified human melanoma vaccine.

  2004cited by this paper
• Production and purification of melanoma gp100 antigen and polyclonal antibodies.

  2004cited by this paper
• Ex vivo detectable activation of Melan-A-specific T cells correlating with inflammatory skin reactions in melanoma patients vaccinated with peptides in IFA.

  2004cited by this paper
• Cancer immunotherapy: moving beyond current vaccines

  2004cited by this paper
• Recombinant NY-ESO-1 protein with ISCOMATRIX adjuvant induces broad integrated antibody and CD4(+) and CD8(+) T cell responses in humans.

  2004cited by this paper
• Peripheral Blood CD4+ T-Cell Response Before Postoperative Active Immunotherapy Correlates with Clinical Outcome in Metastatic Melanoma

  2004cited by this paper
• Humoral immune response to a therapeutic polyvalent cancer vaccine after complete resection of thick primary melanoma and sentinel lymphadenectomy.

  2003cited by this paper
• Enzyme-linked immunospot, cytokine flow cytometry, and tetramers in the detection of T-cell responses to a dendritic cell-based multipeptide vaccine in patients with melanoma.

  2003cited by this paper
• Caspase-mediated cleavage converts Livin from an antiapoptotic to a proapoptotic factor: implications for drug-resistant melanoma.

  2003cited by this paper
• Influence of Mycobacterium bovis Bacillus Calmette-Guérin on Antibody and Cytokine Responses to Human Neonatal Vaccination1

  2002cited by this paper
• Autologous cell vaccine as a post operative adjuvant treatment for high-risk melanoma patients (AJCC stages III and IV)

  2002cited by this paper
• Cytokine control of developmental programs in normal hematopoiesis and leukemia

  2002cited by this paper
• Enhanced humoral immune response correlates with improved disease-free and overall survival in American Joint Committee on Cancer stage II melanoma patients receiving adjuvant polyvalent vaccine.

  2002cited by this paper
• How to analyze ex vivo T-cell responses in cancer patients.

  2002cited by this paper
• Comparative assessment of TCRBV diversity in T lymphocytes present in blood, metastatic lesions, and DTH sites of two melanoma patients vaccinated with an IL-7 gene-modified autologous tumor cell vaccine

  2002cited by this paper
• Treatment of metastatic melanoma with autologous, hapten-modified melanoma vaccine: regression of pulmonary metastases.

  2001cited by this paper
• Human heat shock protein 70 peptide complexes specifically activate antimelanoma T cells.

  2001cited by this paper
• A role for a melanosome transport signal in accessing the MHC class II presentation pathway and in eliciting CD4+ T cell responses.

  1999cited by this paper
• T helper 1 cytokine mRNA is increased in spontaneously regressing primary melanomas.

  1997cited by this paper
• Regulation of MHC class II expression by interferon-gamma mediated by the transactivator gene CIITA.

  1994cited by this paper
• A phase II study of autologous irradiated tumor cells plus BCG in patients with metastatic malignant melanoma

  1977cited by this paper
• Requirements for induction of T cell tolerance to DNFB: efficiency of membrane-associated DNFB.

  1976cited by this paper

• BCG Impact on PD-1/PD-L1 Expression in Peripheral Immunocytes of Cancer Patients—A Potential Explanation for Its Activity in Preventing Alzheimer’s Disease

  2025cites this paper
• A Milestone in the Shift from “Passive Killing” to “Active Immunomodulation” in Cancer Treatment—Progress in Melanoma Vaccine Research

  2025cites this paper
• Monophosphoryl Lipid A–2,4-Dinitrophenylamine Conjugates Are Potent Adjuvants for Carbohydrate and Protein Vaccines

  2025cites this paper
• Repurposing peripheral immunocytes of Bacillus Calmette Guerin-vaccinated melanoma patients to reveal preventive Alzheimer's disease mechanisms, possibly via the unfolded protein response

  2025cites this paper
• MHC class II molecules on pancreatic cancer cells indicate a potential for neo-antigen-based immunotherapy

  2022cites this paper
• Tumorigenic and Immunogenic Properties of Induced Pluripotent Stem Cells: a Promising Cancer Vaccine

  2020cites this paper
• Role of the dynamic tumor microenvironment in controversies regarding immune checkpoint inhibitors for the treatment of non-small cell lung cancer (NSCLC) with EGFR mutations

  2019cites this paper
• Immune checkpoint inhibitors in epidermal growth factor receptor mutant non-small cell lung cancer: Current controversies and future directions.

  2018cites this paper
• Immune Monitoring of Patients Treated With a Whole-Cell Melanoma Vaccine Engineered to Express 4-1BBL

  2016cites this paper
• Adjuvant Autologous Melanoma Vaccine for Macroscopic Stage III Disease: Survival, Biomarkers, and Improved Response to CTLA-4 Blockade

  2016cites this paper
• Recent Advances in Cancer Vaccines - An Update

  2012cites this paper
• EGFR inhibitors, MHC expression and immune responses : Can EGFR inhibitors be used as immune response modifiers?

  2012cites this paper
• Trogocytosis Is a Gateway to Characterize Functional Diversity in Melanoma-Specific CD8+ T Cell Clones

  2012cites this paper
• Minimalistic immunologically defi ned gene expression T helper cell 1 (MIDGE-Th1 ® ) vectors coding for Inter- leukin 12 and -18 in combination with the transfection agent SAINT-18 have systemic antitumoral effects on equine melanomas

  2012cites this paper
• HLA-B35 correlates with a favorable outcome following adjuvant administration of an HLA-matched allogeneic melanoma vaccine.

  2011cites this paper
• Characterization of Interferon-γ–Treated Melanoma Tumor Cells for Use in Dendritic Cell-Based Immunotherapy

  2011cites this paper
• Epidermal Growth Factor Receptor Inhibition Augments the Expression of MHC Class I and II Genes

  2011cites this paper
• The Role of Electrochemotherapy in the Treatment of Malignant Melanoma

  2011cites this paper
• T Cell Clones + CD 8 Functional Diversity in Melanoma-Specific Trogocytosis Is a Gateway to Characterize

  2011cites this paper
• MHC class II expression in pancreatic tumors: a link to intratumoral inflammation

  2011cites this paper
• Autologous Melanoma Vaccine Induces Antitumor and Self-Reactive Immune Responses That Affect Patient Survival and Depend on MHC Class II Expression on Vaccine Cells

  2010cites this paper
• Resistance to the proapoptotic effects of interferon-gamma on melanoma cells used in patient-specific dendritic cell immunotherapy is associated with improved overall survival

  2010cites this paper
• DNA vaccines against cancer come of age.

  2010cites this paper
• Electrochemotherapy as an adjunct or alternative to other treatments for unresectable or in-transit melanoma

  2009cites this paper